 visitante ::
identificación
|
|||||||||||||||
|
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español | |||||||||
| Página principal > Artículos > Artículos publicados > Outcome of liver cancer patients with SARS-CoV-2 infection : |
(Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hôpital Beaujon) (Helwan University) ("Octavian Fodor" Institute for Gastroenterology and Hepatology) (Université de Paris) (Newcastle University Translational and Clinical Research Institute) (University of Sao Paulo School of Medicine) (National Institute of Medical Sciences and Nutrition Salvador Zubirán) (Imperial College London) (Hospital Universitario Central de Asturias) (King Faisal Specialist Hospital & Research Center) (Universidade Federal do Rio Grande do Sul) (Hospital Italiano) (Humanitas Cancer Center) (Hospital Universitario Infanta Leonor) (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) (Campus Virchow-Klinikum and Campus Charité Mitte) (Hepatología) (Bern University Hospital) (University of Naples Federico II) (University of Palermo) (Klinikum Klagenfurt am Wörthersee) (Universidad de Sevilla) (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) (University of Glasgow) (HGU Dr. Balmis) (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) (IDIVAL) (University Hospitals Plymouth NHS Trust (Regne Unit)) (Department of Medical and Surgical Sciences) (Hôpital Beaujon) (Helwan University) (Universidade Federal Fluminense) (National Institute of Medical Sciences and Nutrition Salvador Zubirán) (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico) (Hospital Clínic i Provincial de Barcelona)| Fecha: | 2022 |
| Resumen: | Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66. 5 and 64. 5 years, and 84. 9% and 21. 9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39. 0% of the HCC and 71. 9% of the iCCA patients. After a median follow-up of 7. 20 (IQR: 1. 84-11. 24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18. 4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6. 10% [95% CI 2. 24-12. 74], 11. 76% [95% CI 4. 73-22. 30], 20. 69% [95% CI 11. 35-31. 96] and 34. 52% [95% CI 17. 03-52. 78] for BCLC 0/A, B, C and D, respectively; p =. 0017). The hazard ratio was 1. 45 (95% CI 0. 49-4. 31; p =. 5032) in BCLC-B versus 0/A, and 3. 13 (95% CI 1. 29-7. 62; p =. 0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59. 4%) died, and 12 deaths were related to SARS-CoV-2 infection. This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period. |
| Ayudas: | Ministerio de Economía y Competitividad PI15/00145 Instituto de Salud Carlos III PI19/00819 Instituto de Salud Carlos III PI18/00768 Instituto de Salud Carlos III PI18/00542 Ministerio de Economía y Competitividad PI13/01229 |
| Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Lengua: | Anglès |
| Documento: | Article ; recerca ; Versió publicada |
| Materia: | COVID-19 ; Hepatocellular carcinoma ; Liver cancer ; Mortality |
| Publicado en: | Liver International, Vol. 42 (june 2022) , p. 1891-1901, ISSN 1478-3231 |
